EA9161: A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

IRB/UVA Tracking #
21658
Contact
Sharon Lisa Johnson
Contact Phone
Phase
III
Primary purpose
Treatment
Cancer PI
Craig Portell
Status
OPEN TO ACCRUAL
Ages
Adult